Al-Kali A, Kantarjian H, Shan J, et al: Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117:327–335, 2011.
Baccarani M, Cortes J, Pane F, et al: Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041–6051, 2009.
Baccarani M, Druker NJ, Cortes-Franco J, et al: 24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib(Drug information on imatinib) Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood (ASH Annual Meeting Abstracts) 114:abstract 337, 2009.
Cortes J, Hochhaus A, Hughes T, Kantarjian H:Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 29:524–531, 2011.
Cortes J, Quintas-Cardama A, Jones D, et al: Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: A randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 117:572–580, 2011.
Cortes JE, Baccarani M, Guilhot F, et al: Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 28:424–430, 2010.
Cortes JE, Jones D, O'Brien S, et al: Nilotinib(Drug information on nilotinib) as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28:392–397, 2010.
Cortes JE, Jones D, O'Brien S, et al: Results of dasatinib(Drug information on dasatinib) therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28:398–404, 2010.
Cortes JE, Wetzler M, Lipton J, et al: Subcutaneous omacetaxine (OM) treatment of chronic phase (cp) chronic myeloid leukemia (CML) patients following multiple tyrosine kinase inhibitor (TKI) failure. Blood (ASH Annual Meeting Abstracts) 116:abstract 2290, 2010.
Hehlmann R, Lauseker M, Jung-Munkwitz S, et al: Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29:1634–1642, 2011.
Jabbour E, Kantarjian H, O'Brien S, et al: Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 117:1822–1827, 2011.
Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277–300, 2010.
Kantarjian H, Cortes J, Kim DW, et al: Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-Month median follow-up. Blood 113:6322–6329, 2009.
Kantarjian H, Pasquini R, Lévy V, et al: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R). Cancer 115:4136–4147, 2009.
Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260–2270, 2010.
Kantarjian HM, Shan J, Jones D, et al: Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 27:3659–3663, 2009.
Khoury HJ, Guilhot F, Hughes TP, et al: Dasatinib treatment for Philadelphia chromosome-positive leukemias: Practical considerations. Cancer 115:1381–1394, 2009.
Mahon FX, Rea D, Guilhot J, et al: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029–1035, 2010.
Marin D, Bazeos A, Mahon FX, et al: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381–2388, 2010.
Preudhomme C, Guilhot J, Nicolini FE, et al: Imatinib plus peginterferon alfa-2a(Drug information on peginterferon alfa-2a) in chronic myeloid leukemia. N Engl J Med 363:2511–2521, 2010.
Quintas-Cardama A, Cortes J: Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619–1630, 2009.
Quintas-Cardama A, Cortes JE, O'Brien S, et al: Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 115:2912–2921, 2009.
Quintas-Cardama A, Kantarjian H, Jones D, et al: Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113:6315–6321, 2009.
Redaelli S, Piazza R, Rostagno R, et al: Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27:469–471, 2009.
Ross DM, Branford S, Seymour JF, et al: Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24:1719–1724, 2010.
Rosti G, Palandri F, Castagnetti F, et al: Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 114:4933–4938, 2009.
Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251–2259, 2010.
Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011. CA Cancer J Clin 61:212–236, 2011.
Velev N, Cortes J, Champlin R, et al: Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 116:3631–3637, 2010.
White DL, Dang P, Engler J, et al: Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 28:2761–2767, 2010.
Abbreviations in this chapter
EBMT = European Group for Bone and Marrow Transplantation; MRC = Medical Research Council; SEER = Surveillance, Epidemiology and End Results; WHO = World Health Organization